Title

Comparative Study of Periwinkle Extract on MCF-7 Breast Cancer and C2C12 Myoblast Growth Rate and Morphology

Document Type

Oral Presentation

Location

SURC Ballroom C/D

Start Date

15-5-2014

End Date

15-5-2014

Keywords

Breast cancer, Periwinkle, Neutraceutical

Abstract

Nutritional supplements, or neutraceuticals, are touted by many for their purported ability to maintain wellness and treat disease. Neutraceutical treatment of human diseases is gaining popularity; however comparatively few scientific studies support their routine use. This study compares the effects of periwinkle extract as a neutraceutical treatment to determine if it has a differential impact on cancerous and normal cell lines. Periwinkle, a flower currently used to help treat leukemia and lymphoma, is a prime candidate for study. An exploratory study was conducted to investigate periwinkle’s effect on growth rate and morphology for MCF-7 human breast cancer and C2C12 mouse myoblast cell lines. Initial studies showed a dose-dependent decrease of MCF-7 viability as well as dramatic changes in cancer cell morphology; however periwinkle’s effects on normal cells is unknown. Ideally, periwinkle would differentially affect breast cancer but not normal cells. This ongoing study is investigating that question. Based on preliminary results, we anticipate that: a) MCF-7 human breast cancer cell growth rate will decrease as periwinkle concentration increases; b) MCF-7 morphology will change as periwinkle concentration changes; C2C12 muscle cell viability be unaffected at normal but will decrease at high periwinkle concentrations; and C2C12 muscle cell morphology remain unchanged as periwinkle concentration changes. Forthcoming study results will support or refute our hypotheses.

This presentation received a People's Choice Award for Best Poster Presentation, 2014.

Poster Number

20

Faculty Mentor(s)

Quitadamo, Ian

Additional Mentoring Department

Biological Sciences

This document is currently not available here.

Share

COinS
 
May 15th, 8:30 AM May 15th, 11:00 AM

Comparative Study of Periwinkle Extract on MCF-7 Breast Cancer and C2C12 Myoblast Growth Rate and Morphology

SURC Ballroom C/D

Nutritional supplements, or neutraceuticals, are touted by many for their purported ability to maintain wellness and treat disease. Neutraceutical treatment of human diseases is gaining popularity; however comparatively few scientific studies support their routine use. This study compares the effects of periwinkle extract as a neutraceutical treatment to determine if it has a differential impact on cancerous and normal cell lines. Periwinkle, a flower currently used to help treat leukemia and lymphoma, is a prime candidate for study. An exploratory study was conducted to investigate periwinkle’s effect on growth rate and morphology for MCF-7 human breast cancer and C2C12 mouse myoblast cell lines. Initial studies showed a dose-dependent decrease of MCF-7 viability as well as dramatic changes in cancer cell morphology; however periwinkle’s effects on normal cells is unknown. Ideally, periwinkle would differentially affect breast cancer but not normal cells. This ongoing study is investigating that question. Based on preliminary results, we anticipate that: a) MCF-7 human breast cancer cell growth rate will decrease as periwinkle concentration increases; b) MCF-7 morphology will change as periwinkle concentration changes; C2C12 muscle cell viability be unaffected at normal but will decrease at high periwinkle concentrations; and C2C12 muscle cell morphology remain unchanged as periwinkle concentration changes. Forthcoming study results will support or refute our hypotheses.

This presentation received a People's Choice Award for Best Poster Presentation, 2014.